← Issue №17/ week of Oct 25, 2026/Hepatology

Personalized Prehabilitation: A Pathway to Improved Frailty Metrics and Survival in Liver Transplant Candidates.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=1,275 · Oct 21, 2026 · Clin Gastro Hep · IF 16.2

Personalized Prehabilitation: A Pathway to Improved Frailty Metrics and Survival in Liver Transplant Candidates.

New evidenceliver transplant
Clinical takeawayAn LFI change of 0.4 is a candidate minimal clinically important difference for frailty programmes; this cohort cannot show that prehabilitation itself lowers mortality, and 6MWT gains did not track survival.
What it foundLiver frailty index (LFI) improvement by at least 0.4 was associated with a ∼50% reduction in mortality (HR=0.56, p=0.037).
ContextThis study provides evidence supporting the use of prehabilitation to improve frailty metrics and survival in liver transplant candidates, refining prior evidence on frailty interventions. The findings apply specifically to LT candidates with a median age of 57 and MELD score of 14.
Emergingsuggested applicable standard· AASLD/AST, 'AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation' (Dove L et al., Hepatology 2026;83(6):1609-1645). DOI 10.1097/HEP.0000000000001644, PMID 41405234.

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Refer patients with decompensated cirrhosis (including those with MELD-Na <15 or MELD 3.0 <15 if they have clinically significant portal hypertension, recurrent ascites, hepatic encephalopathy, or variceal bleeding), acute liver failure meeting King's College Criteria/UNOS Status 1A, or HCC within Milan/UCSF criteria for comprehensive multidisciplinary liver transplant evaluation, with MELD 3.0 driving UNOS waitlist allocation and MELD exception scoring for HCC/HPS/FAP. Optimize modifiable risk factors before listing (alcohol abstinence, HCV DAA treatment, vaccinations, DM/obesity/OSA and dental clearance) and use bridging/downstaging locoregional therapy for HCC while awaiting transplant. After transplant, maintain lifelong immunosuppression with tacrolimus plus mycophenolate ± tapered steroids alongside infection prophylaxis and recurrent-disease surveillance.

AASLD/AST, 'AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation' (Dove L et al., Hepatology 2026;83(6):1609-1645). DOI 10.1097/HEP.0000000000001644, PMID 41405234. · reviewed 2026-07-21 ↗
Lin FP … Duarte-Rojo A · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues